BRCA1 is altered in 1.24% of prostate carcinoma patients with BRCA1 Loss present in 0.06% of all prostate carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 22 clinical trials for prostate carcinoma, of which 19 are open and 3 are closed. Of the trials that contain BRCA1 Loss and prostate carcinoma as inclusion criteria, 4 are phase 1 (3 open), 3 are phase 1/phase 2 (2 open), 13 are phase 2 (12 open), and 2 are phase 3 (2 open) [5].

Olaparib has evidence of efficacy in patients with BRCA1 Loss in prostate carcinoma [5].

BRCA1 is altered in 3.21% of malignant solid tumor patients with BRCA1 Loss present in 0.04% of all malignant solid tumor patients [4].

BRCA1 Loss is an inclusion criterion in 52 clinical trials for malignant solid tumor, of which 41 are open and 11 are closed. Of the trials that contain BRCA1 Loss and malignant solid tumor as inclusion criteria, 22 are phase 1 (16 open), 12 are phase 1/phase 2 (7 open), and 18 are phase 2 (18 open) [5].

BRCA1 is altered in 3.12% of breast carcinoma patients with BRCA1 Loss present in 0.1% of all breast carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 38 clinical trials for breast carcinoma, of which 30 are open and 8 are closed. Of the trials that contain BRCA1 Loss and breast carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 12 are phase 1 (7 open), 6 are phase 1/phase 2 (5 open), 17 are phase 2 (15 open), and 2 are phase 3 (2 open) [5].

BRCA1 is altered in 7.82% of ovarian carcinoma patients with BRCA1 Loss present in 0.25% of all ovarian carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 32 clinical trials for ovarian carcinoma, of which 25 are open and 7 are closed. Of the trials that contain BRCA1 Loss and ovarian carcinoma as inclusion criteria, 2 are early phase 1 (2 open), 9 are phase 1 (6 open), 6 are phase 1/phase 2 (5 open), 11 are phase 2 (9 open), 3 are phase 3 (2 open), and 1 is phase 4 (1 open) [5].

BRCA1 is altered in 4.55% of primary peritoneal carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 23 clinical trials for primary peritoneal carcinoma, of which 16 are open and 7 are closed. Of the trials that contain BRCA1 Loss and primary peritoneal carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 3 are phase 1/phase 2 (3 open), 8 are phase 2 (4 open), 3 are phase 3 (2 open), and 1 is phase 4 (1 open) [5].

BRCA1 is altered in 3.64% of fallopian tube carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 22 clinical trials for fallopian tube carcinoma, of which 15 are open and 7 are closed. Of the trials that contain BRCA1 Loss and fallopian tube carcinoma as inclusion criteria, 1 is early phase 1 (1 open), 7 are phase 1 (5 open), 2 are phase 1/phase 2 (2 open), 8 are phase 2 (4 open), 3 are phase 3 (2 open), and 1 is phase 4 (1 open) [5].

BRCA1 is altered in 1.22% of prostate adenocarcinoma patients with BRCA1 Loss present in 0.06% of all prostate adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 18 clinical trials for prostate adenocarcinoma, of which 16 are open and 2 are closed. Of the trials that contain BRCA1 Loss and prostate adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open), 15 are phase 2 (13 open), and 2 are phase 3 (2 open) [5].

BRCA1 is altered in 9.01% of high grade ovarian serous adenocarcinoma patients with BRCA1 Loss present in 0.35% of all high grade ovarian serous adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 11 clinical trials for high grade ovarian serous adenocarcinoma, of which 6 are open and 5 are closed. Of the trials that contain BRCA1 Loss and high grade ovarian serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 1 is phase 1/phase 2 (0 open), 5 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

BRCA1 is altered in 3.53% of non-small cell lung carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 10 clinical trials for non-small cell lung carcinoma, of which 8 are open and 2 are closed. Of the trials that contain BRCA1 Loss and non-small cell lung carcinoma as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (2 open), and 5 are phase 2 (5 open) [5].

BRCA1 is altered in 2.0% of pancreatic carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 9 clinical trials for pancreatic carcinoma, of which 8 are open and 1 is closed. Of the trials that contain BRCA1 Loss and pancreatic carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 5 are phase 2 (5 open) [5].

BRCA1 is altered in 5.12% of endometrial carcinoma patients with BRCA1 Loss present in 0.05% of all endometrial carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 8 clinical trials for endometrial carcinoma, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 Loss and endometrial carcinoma as inclusion criteria, 3 are phase 1 (2 open), 2 are phase 1/phase 2 (2 open), 2 are phase 2 (2 open), and 1 is phase 3 (1 open) [5].

BRCA1 is altered in 2.16% of adenocarcinoma of the gastroesophageal junction patients [4].

BRCA1 Loss is an inclusion criterion in 8 clinical trials for adenocarcinoma of the gastroesophageal junction, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 Loss and adenocarcinoma of the gastroesophageal junction as inclusion criteria, 2 are phase 1 (1 open), 3 are phase 1/phase 2 (3 open), and 3 are phase 2 (3 open) [5].

BRCA1 is altered in 2.0% of pancreatic adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 8 clinical trials for pancreatic adenocarcinoma, of which 7 are open and 1 is closed. Of the trials that contain BRCA1 Loss and pancreatic adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 6 are phase 2 (6 open) [5].

BRCA1 is altered in 3.64% of high grade fallopian tube serous adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 7 clinical trials for high grade fallopian tube serous adenocarcinoma, of which 4 are open and 3 are closed. Of the trials that contain BRCA1 Loss and high grade fallopian tube serous adenocarcinoma as inclusion criteria, 4 are phase 1 (3 open), 2 are phase 2 (0 open), and 1 is phase 3 (1 open) [5].

BRCA1 is altered in 1.99% of small cell lung carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 6 clinical trials for small cell lung carcinoma, of which 4 are open and 2 are closed. Of the trials that contain BRCA1 Loss and small cell lung carcinoma as inclusion criteria, 1 is phase 1 (0 open), 3 are phase 1/phase 2 (3 open), and 2 are phase 2 (1 open) [5].

BRCA1 is altered in 5.82% of urothelial carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 6 clinical trials for urothelial carcinoma, of which 5 are open and 1 is closed. Of the trials that contain BRCA1 Loss and urothelial carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

BRCA1 is altered in 3.68% of colorectal carcinoma patients with BRCA1 Loss present in 0.02% of all colorectal carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 5 clinical trials for colorectal carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRCA1 Loss and colorectal carcinoma as inclusion criteria, 3 are phase 1 (2 open), 1 is phase 1/phase 2 (0 open), and 1 is phase 2 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 5 clinical trials for fallopian tube endometrioid adenocarcinoma, of which 2 are open and 3 are closed. Of the trials that contain BRCA1 Loss and fallopian tube endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 2 (0 open), and 1 is phase 3 (1 open) [5].

BRCA1 is altered in 1.98% of gastric adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 5 clinical trials for gastric adenocarcinoma, of which 5 are open and 0 are closed. Of the trials that contain BRCA1 Loss and gastric adenocarcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) and 3 are phase 2 (3 open) [5].

BRCA1 is altered in 1.96% of gastric carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 Loss and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 3.05% of head and neck carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 5 clinical trials for head and neck carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 Loss and head and neck carcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [5].

BRCA1 is altered in 4.97% of melanoma patients [4].

BRCA1 Loss is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 Loss and melanoma as inclusion criteria, 1 is phase 1 (0 open) and 4 are phase 2 (4 open) [5].

BRCA1 is altered in 1.71% of non-hodgkin lymphoma patients with BRCA1 Loss present in 0.07% of all non-hodgkin lymphoma patients [4].

BRCA1 Loss is an inclusion criterion in 4 clinical trials for non-hodgkin lymphoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Loss and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (0 open), and 2 are phase 2 (2 open) [5].

BRCA1 is altered in 1.47% of lymphoma patients with BRCA1 Loss present in 0.05% of all lymphoma patients [4].

BRCA1 Loss is an inclusion criterion in 4 clinical trials for lymphoma, of which 1 is open and 3 are closed. Of the trials that contain BRCA1 Loss and lymphoma as inclusion criteria, 3 are phase 1 (1 open) and 1 is phase 1/phase 2 (0 open) [5].

BRCA1 is altered in 3.19% of cervical carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 4 clinical trials for cervical carcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Loss and cervical carcinoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 4 clinical trials for hereditary breast and ovarian cancer syndrome, of which 1 is open and 3 are closed. Of the trials that contain BRCA1 Loss and hereditary breast and ovarian cancer syndrome as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), 1 is phase 2/phase 3 (1 open), and 1 is no phase specified (0 open) [5].

BRCA1 is altered in 4.55% of primary peritoneal serous adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 4 clinical trials for primary peritoneal serous adenocarcinoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Loss and primary peritoneal serous adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 2 (0 open), and 1 is phase 3 (1 open) [5].

BRCA1 is altered in 0.95% of soft tissue sarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 4 clinical trials for soft tissue sarcoma, of which 3 are open and 1 is closed. Of the trials that contain BRCA1 Loss and soft tissue sarcoma as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 5.98% of bladder carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 3 clinical trials for bladder carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 Loss and bladder carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [5].

BRCA1 Loss is an inclusion criterion in 3 clinical trials for breast lobular carcinoma in situ, of which 1 is open and 2 are closed. Of the trials that contain BRCA1 Loss and breast lobular carcinoma in situ as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (0 open), and 1 is phase 2/phase 3 (1 open) [5].

BRCA1 is altered in 4.18% of head and neck squamous cell carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 Loss and head and neck squamous cell carcinoma as inclusion criteria, 3 are phase 1/phase 2 (2 open) [5].

BRCA1 is altered in 5.69% of ovarian endometrioid adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 3 clinical trials for ovarian endometrioid adenocarcinoma, of which 1 is open and 2 are closed. Of the trials that contain BRCA1 Loss and ovarian endometrioid adenocarcinoma as inclusion criteria, 2 are phase 1 (1 open) and 1 is phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 3 clinical trials for primary peritoneal endometrioid adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain BRCA1 Loss and primary peritoneal endometrioid adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 2 (0 open), and 1 is phase 3 (1 open) [5].

BRCA1 is altered in 7.48% of malignant ovarian epithelial tumor patients with BRCA1 Loss present in 0.23% of all malignant ovarian epithelial tumor patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for malignant ovarian epithelial tumor, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 Loss and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (0 open) [5].

BRCA1 is altered in 1.73% of bile duct carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for bile duct carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and bile duct carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BRCA1 is altered in 6.0% of bladder urothelial carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for bladder urothelial carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and bladder urothelial carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BRCA1 is altered in 0.8% of clear cell renal cell carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for clear cell renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and clear cell renal cell carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for ductal carcinoma in situ, of which 0 are open and 2 are closed. Of the trials that contain BRCA1 Loss and ductal carcinoma in situ as inclusion criteria, 1 is phase 1 (0 open) and 1 is no phase specified (0 open) [5].

BRCA1 is altered in 2.95% of esophageal adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for esophageal adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and esophageal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.53% of esophageal carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and esophageal carcinoma as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

BRCA1 is altered in 0.65% of Ewing sarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for Ewing sarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and Ewing sarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 0.43% of gastrointestinal stromal tumor patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for gastrointestinal stromal tumor, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.5% of malignant central nervous system neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for malignant central nervous system neoplasm, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and malignant central nervous system neoplasm as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.61% of osteosarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for osteosarcoma, of which 2 are open and 0 are closed. Of the trials that contain BRCA1 Loss and osteosarcoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.94% of pancreatic ductal adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for pancreatic ductal adenocarcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 Loss and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 2 (1 open) [5].

BRCA1 is altered in 4.85% of squamous cell lung carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 2 clinical trials for squamous cell lung carcinoma, of which 1 is open and 1 is closed. Of the trials that contain BRCA1 Loss and squamous cell lung carcinoma as inclusion criteria, 1 is phase 2 (0 open) and 1 is no phase specified (1 open) [5].

BRCA1 is altered in 8.23% of malignant ovarian serous tumor patients with BRCA1 Loss present in 0.29% of all malignant ovarian serous tumor patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian serous tumor, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and malignant ovarian serous tumor as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 is altered in 7.35% of malignant ovarian neoplasm patients with BRCA1 Loss present in 0.22% of all malignant ovarian neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant ovarian neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and malignant ovarian neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 is altered in 2.9% of diffuse large B-cell lymphoma patients with BRCA1 Loss present in 0.2% of all diffuse large B-cell lymphoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for diffuse large B-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 2.52% of leiomyosarcoma patients with BRCA1 Loss present in 0.2% of all leiomyosarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for leiomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and leiomyosarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.22% of neuroendocrine tumor patients with BRCA1 Loss present in 0.15% of all neuroendocrine tumor patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for neuroendocrine tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and neuroendocrine tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 4.86% of carcinoma of unknown primary patients with BRCA1 Loss present in 0.14% of all carcinoma of unknown primary patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for carcinoma of unknown primary, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and carcinoma of unknown primary as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 3.14% of invasive breast carcinoma patients with BRCA1 Loss present in 0.11% of all invasive breast carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for invasive breast carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and invasive breast carcinoma as inclusion criteria, 1 is no phase specified (0 open) [5].

BRCA1 is altered in 1.66% of B-cell non-hodgkin lymphoma patients with BRCA1 Loss present in 0.09% of all B-cell non-hodgkin lymphoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for B-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and B-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 4.87% of endometrial adenocarcinoma patients with BRCA1 Loss present in 0.06% of all endometrial adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for endometrial adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and endometrial adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 4.08% of malignant uterine neoplasm patients with BRCA1 Loss present in 0.03% of all malignant uterine neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant uterine neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant uterine neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.22% of sarcoma patients with BRCA1 Loss present in 0.03% of all sarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for sarcoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and sarcoma as inclusion criteria, 1 is phase 1 (0 open) [5].

BRCA1 is altered in 3.66% of colorectal adenocarcinoma patients with BRCA1 Loss present in 0.02% of all colorectal adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for colorectal adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 3.67% of malignant intestinal neoplasm patients with BRCA1 Loss present in 0.02% of all malignant intestinal neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 3.18% of ampulla of vater carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for ampulla of vater carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and ampulla of vater carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 7.1% of anal carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for anal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and anal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BRCA1 is altered in 2.86% of anaplastic astrocytoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (0 open) [5].

BRCA1 is altered in 1.73% of bile duct adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for bile duct adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and bile duct adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 1.7% of biliary tract carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for biliary tract carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and biliary tract carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for breast fibrocystic change, proliferative type, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and breast fibrocystic change, proliferative type as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for breast intraductal proliferative lesion, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and breast intraductal proliferative lesion as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for bronchogenic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and bronchogenic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.73% of cholangiocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 0.83% of esophageal squamous cell carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for esophageal squamous cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and esophageal squamous cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.57% of gallbladder carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for gallbladder carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and gallbladder carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 0.68% of germ cell tumor patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.86% of glioblastoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for glioblastoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and glioblastoma as inclusion criteria, 1 is phase 1 (0 open) [5].

BRCA1 is altered in 2.64% of glioma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for glioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and glioma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for histiocytic sarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and histiocytic sarcoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for intraductal proliferative lesion of the breast, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and intraductal proliferative lesion of the breast as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for juvenile xanthogranuloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and juvenile xanthogranuloma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for langerhans cell histiocytosis, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and langerhans cell histiocytosis as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.06% of low grade ovarian serous adenocarcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for low grade ovarian serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and low grade ovarian serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 3.45% of lung carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.18% of malignant esophagogastric neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant esophagogastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant esophagogastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 1.96% of malignant gastric neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant gastric neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant gastric neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 1.94% of malignant mesothelioma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant mesothelioma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.01% of malignant mixed mesodermal (mullerian) tumor patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant mixed mesodermal (mullerian) tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant mixed mesodermal (mullerian) tumor as inclusion criteria, 1 is early phase 1 (1 open) [5].

BRCA1 is altered in 4.55% of malignant peritoneal neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant peritoneal neoplasm, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and malignant peritoneal neoplasm as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 is altered in 3.59% of malignant small intestinal neoplasm patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for malignant small intestinal neoplasm, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and malignant small intestinal neoplasm as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

BRCA1 is altered in 0.56% of mantle cell lymphoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and mantle cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 1.47% of mature T-cell and NK-cell non-hodgkin lymphoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for mature T-cell and NK-cell non-hodgkin lymphoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and mature T-cell and NK-cell non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 1.2% of medulloblastoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and medulloblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 2.37% of multiple myeloma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for multiple myeloma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and multiple myeloma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 2.98% of neuroblastoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for neuroblastoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 3.64% of neuroendocrine carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for neuroendocrine carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and neuroendocrine carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 4.35% of ovarian carcinosarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for ovarian carcinosarcoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and ovarian carcinosarcoma as inclusion criteria, 1 is phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for ovarian clear cell adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and ovarian clear cell adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for ovarian endometrioid adenocarcinofibroma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and ovarian endometrioid adenocarcinofibroma as inclusion criteria, 1 is phase 3 (1 open) [5].

BRCA1 is altered in 4.0% of penile carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for penile carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and penile carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for peripheral primitive neuroectodermal tumor, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and peripheral primitive neuroectodermal tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for primary peritoneal high grade serous adenocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and primary peritoneal high grade serous adenocarcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 is altered in 1.87% of renal cell carcinoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and renal cell carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

BRCA1 is altered in 1.59% of rhabdomyosarcoma patients [4].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 Loss and rhabdomyosarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for vaginal carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and vaginal carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].

BRCA1 Loss is an inclusion criterion in 1 clinical trial for vulvar carcinoma, of which 0 are open and 1 is closed. Of the trial that contains BRCA1 Loss and vulvar carcinoma as inclusion criteria, 1 is phase 1/phase 2 (0 open) [5].